{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:24:30Z","timestamp":1792041870988,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic inflammatory and proliferative skin disease that causes pathological skin changes and has a substantial impact on the quality of patient life. Apremilast was approved by the US Food and Drug Administration as an oral medication for psoriasis and is beneficial in mild to moderate conditions for chronic usage. However, 5%\u20137% of withdrawals were reported due to severe side effects. To address the issue, a localized drug delivery strategy via the topical route may be a viable approach. However, poor physicochemical properties make it vulnerable to passing through the skin, requiring a specialized drug delivery system to demonstrate its full potential via a topical route like lecithin organogel. The formulation was optimized by screening the suitable lecithin type and non\u2010polar solvents based on the gel formation ability of lecithin and the solubility of apremilast in the solvent. The pseudo\u2010ternary diagram was used to optimize the water content required to form the gel. The optimized gel was found to be shear thinning characterized for rheological parameters, in\u2010vitro diffusion studies, and in\u2010vitro skin distribution studies. Preclinical studies in Imiquimod\u2010induced mice showed a better reduction in severity index, cytokine levels, and epidermal hyperplasia from the lecithin organogel group compared to the apremilast oral administration and marketed standard topical gel group. Based on these results, lecithin organogel can be considered a promising approach to deliver molecules like apremilast by topical route in psoriatic\u2010like conditions.<\/jats:p>","DOI":"10.1002\/ddr.22191","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:43:27Z","timestamp":1714437807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Formulation characterization of lecithin organogel as topical drug delivery system for psoriasis: In\u2010vitro permeation and preclinical evaluation"],"prefix":"10.1002","volume":"85","author":[{"given":"Prajakta","family":"Bule","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology (Formulations) National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kadkanje","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikiran","family":"Kshirsagar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology (Formulations) National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswara Rao","family":"Puppala","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vegi Ganga Modi","family":"Naidu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2688","authenticated-orcid":false,"given":"Naveen","family":"Chella","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology (Formulations) National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Abraham J. Chaudhari K. &Mittal V.(2017).Topical compositions of apremilast.Wold patent Patent application WO2017216738A1."},{"issue":"3","key":"e_1_2_9_3_1","first-page":"191","article-title":"Preparation and characterization of reverse micelle based organogels of piroxicam","volume":"59","author":"Agrawal G. P.","year":"2004","journal-title":"Die Pharmazie"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-010-9540-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000012157.80716.73"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1206886"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3694901"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.0c01164"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.10.025"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.12.019"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/495271"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0144-3"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13336"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.604745"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720109787846252"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2005.07.009"},{"key":"e_1_2_9_17_1","unstructured":"Joharapurkar A. A. Sutariya B. K. Jain M. R. Kulkarni S. K. Hothur K. R. &Sirwani R. P. (2019).Topical formulation of apremilast(U.S. Patent Application 16\/106 123)."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114385"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1718481"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103503"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","unstructured":"Langley A. &Beecker J. (2018). Management of common side effects of apremilast.Journal of Cutaneous Medicine and Surgery 22(4) 415\u2013421.","DOI":"10.1177\/1203475417748886"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2005.00693.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00809-1"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2015.05.012"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S320810"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102442"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2011.12.005"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.08.019"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101691"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X10381432"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2018.04.002"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720106778559010"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.9734\/jpri\/2021\/v33i28B31531"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","unstructured":"Singh Y. Bagaria A. Bagaria B. &Gupta Y. (2023). Effect of oral drug apremilast on histopathological changes in patients of plaque psoriasis: A prospective observational study.Journal of Clinical and Diagnostic Research.","DOI":"10.7860\/JCDR\/2023\/60263.17537"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108436"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/foods11070939"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-61211-1.00018-8"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.22191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:06:07Z","timestamp":1760367967000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.22191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/ddr.22191"],"URL":"https:\/\/doi.org\/10.1002\/ddr.22191","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2023-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e22191"}}